Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

NCT01863147 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Type 2 Diabetes
Coronary Artery Disease

Interventions

DRUG: Sitagliptin and acarbose

Sponsor

Wuhan General Hospital of Guangzhou Military Command